Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology

CAR-T Dream Achieved

After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Building R&D Capability
Indian Institutes Of Technology Are Building R&D Capabilities In Healthcare • Source: Shutterstock

The launch of India’s first indigenous chimeric antigen receptor (CAR)-T cell therapy NexCAR19 (actalycabtagene autoleucel) last month at nearly 10% of the price of similar treatments available in the country was a truly significant moment.

Its impact on access was recognized not just by India’s president and the government, but also by Time magazine, which...

More from R&D

More from Scrip

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By 

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.